Correction: A genetic variant in SLC28A3, rs56350726, is associated with progression to castration-resistant prostate cancer in a Korean population with metastatic prostate cancer

Jung Ki Jo; Jong Jin Oh; Yong Tae Kim; Hong Sang Moon; Hong Yong Choi; Seunghyun Park; Jin-Nyoung Ho; Sungroh Yoon; Hae Young Park; Seok-Soo Byun

doi:10.18632/oncotarget.25970

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: A genetic variant in SLC28A3, rs56350726, is associated with progression to castration-resistant prostate cancer in a Korean population with metastatic prostate cancer

PDF | How to cite

Oncotarget. 2018; 9:31938-31938. https://doi.org/10.18632/oncotarget.25970

Metrics: PDF 1423 views | ?

Jung Ki Jo^1,*, Jong Jin Oh^2,*, Yong Tae Kim¹, Hong Sang Moon³, Hong Yong Choi³, Seunghyun Park⁴, Jin-Nyoung Ho⁵, Sungroh Yoon⁴, Hae Young Park¹ and Seok- Soo Byun²

¹ Department of Urology, Hanyang University Hospital, Seoul, Korea
² Department of Urology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
³ Department of Urology, Hanyang University Guri Hospital, Guri-si, Korea
⁴ Department of Electrical and Computer Engineering, Seoul National University, Seoul, Korea
⁵ Biomedical Research Institute, Seoul National University Bundang Hospital, Seongnam, Korea
^* These authors contributed equally to this work

Published: August 07, 2018

This article has been corrected: The correct author name is given below:

Jung Ki Jo

Original article: Oncotarget. 2017; 8:96893-96902. DOI: https://doi.org/10.18632/oncotarget.18298.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25970

Publication Alerts

Corrections:

Correction: A genetic variant in SLC28A3, rs56350726, is associated with progression to castration-resistant prostate cancer in a Korean population with metastatic prostate cancer